&nbsp;

CAR T Cell Therapy Appeals Policy Apr2020 _ FR.pdf

Jul 2020

Regimen

CRBPGEMC+PEMB

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - In Combination with Carboplatin and Paclitaxel for First-Line Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Drugs Used:

pembrolizumab (PDRP prior authorization),

CARBOplatin,

gemcitabine

... Show more tags

Quick Link(s):

Regimen Monograph

Aug 2022

Regimen

CISPGEMC+PEMB

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - In Combination with Carboplatin and Paclitaxel for First-Line Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Drugs Used:

pembrolizumab (PDRP prior authorization),

CISplatin,

gemcitabine

... Show more tags

Quick Link(s):

Regimen Monograph

Aug 2022

Regimen

CHP+BREN

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Intermediate Grade,

Lymphoma - T-cell

Intent: Curative, Palliative

Funding:

New Drug Funding Program

Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Peripheral T-cell Lymphoma (PTCL)

ODB - General Benefit

prednisone

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2022

Regimen

CYTADAUN+GEMT

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Curative

Funding:

New Drug Funding Program

Gemtuzumab Ozogamicin (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Drugs Used:

DAUNOrubicin,

cytarabine,

gemtuzumab ozogamicin

... Show more tags

Quick Link(s):

Regimen Monograph

Nov 2021

Document

SeptemberCancerFactsImg.png

Aug 2020

Document

SeptemberCancerFactsImg-FR.png

Aug 2020

Stratégie pour la lutte contre le cancer chez les Premières Nations, les Inuits, les Métis et les Autochtones en milieu urbain 2019 – 2023

COVID-19 and Cancer

Find links to information about getting cancer care in Ontario during COVID-19.

Document

CRBPGEMC-FR.pdf

Sep 2020

Document